ArticleMayo Clinic proceedings. Innovations, quality & outcomes2025

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Sue Ann Costa Clemens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.